[an error occurred while processing this directive] | [an error occurred while processing this directive]
Hotspots of stereotactic body radiotherapy in radiobiology
Le Ziyu, Liu Yong
Department of Radiation Oncology,Shanghai General Hospital,Shanghai Jiao Tong University,Shanghai 201620,China (Le ZY,Liu Y);Department of Radiation Oncology,Shanghai Cancer Center,Fudan University,Shanghai 200032,China (Le ZY)
Abstract Stereotactic body radiotherapy (SBRT) has been gradually proven to be effective in treating multiple solid tumors. Along with the development of image-guided radiotherapy (IGRT) system and radiotherapy,SBRT can form a high-dose region in the target area,whereas the dose gradient outside the target area declines rapidly. It not only delivers large-dose irradiation to the tumors,but also protects the surrounding normal tissues as possible,thereby implementing safe"big fractionated radiotherapy".At present,regular understanding of the radiobiology underlying SBRT is still lacking. Multiple issues,such as applicability of linear quadratic (LQ) model,weakening of re-oxygenation,additional cell killing effect different from conventional fractionated radiotherapy and immune enhancement effect are still controversial. In this article,the above controversial hotspots were discussed and analyzed,aiming to deepen the understanding of the radiobiological characteristics of SBRT and contribute to promoting the application of SBRT in clinical practice.
[1] 夏廷毅.SBRT临床应用结果的思考[J].医疗装备,2009,22(7):1-5.DOI:10.3969/j.issn.1002-2376.2009.07.001. Xia TY.Thoughts on the clinical application of SBRT[J]. Med Equip,2009,22(7):1-5.DOI:10.3969/j.issn.1002-2376.2009.07.001. [2] Folkert MR,Timmerman RD.Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT)[J].Adv Drug Deliv Rev,2017,109:3-14.DOI:10.1016/j.addr.2016.11.005. [3] Sun B,Brooks ED,Komaki RU et al.7-year follow-up after stereotactic ablative radiotherapy for patients with stage Ⅰ non–small cell lung cancer:results of a phase 2 clinical trial[J].Cancer,2017,123(16):3031-3039.DOI:10.1002/cncr.30693. [4] Garcia-Barros M,Paris F,Cordon-Cardo C,et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis[J].Science,2003,300(5622):1155-1159. [5] Lee Y,Auh SL,Wang Y,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood,2009,114(3):589-595.DOI:10.1182/blood-2009-02-206870. [6] Fuks Z,Kolesnick R.Engaging the vascular component of the tumor response[J].Cancer Cell,2005,8(2):89-91. [7] Hill RP,Marie-Egyptienne DT,Hedley DW.Cancer stem cells,hypoxia and metastasis[J].Semin. Radiat. Oncol,2009,19(2):106-111.DOI:10.1016/j.semradonc.2008.12.002. [8] Carlson DJ,Keall PJ,Loo BW Jr,et al. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia[J].Int J Radiat Oncol Biol Phys,2011,79(4):1188-1195.DOI:10.1016/j.ijrobp.2010.10.007. [9] Bernstein MB,Krishnan S,Hodge JW,et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR):a curative approach[J]? Nat Rev Clin Oncol,2016,13(8):516-24.DOI:10.1038/nrclinonc.2016.30. [10] 易培强,付杰.体部立体定向放疗的放射生物学进展[J].中华放射肿瘤学杂志,2016,25(12):1379-1383.DOI:10.3760/cma.j.issn.1004?4221.2016.12.023. Yi PQ,Fu J.Advances in radiobiology of body stereotactic radiotherapy[J].Chin J Radiat Oncol,2016,25(12):1379-1383.DOI:10.3760/cma.j.issn.1004?4221.2016.12.023. [11] Brown JM,Carlson DJ,Brenner DJ.The tumor radiobiology of SRS and SBRT:are more than the 5 Rs involved[J]? Int J Radiat Oncol Biol Phys,2014,88(2):254-262.DOI:10.1016/j.ijrobp.2013.07.022. [12] Park C,Papiez L,Zhang S,et al. Universal survival curve and single fraction equivalent dose:useful tools in understanding potency of ablative radiotherapy[J].Int J Radiat Oncol Biol Phys,2008,70(3):847-852.DOI:10.1016/j.ijrobp.2007.10.059. [13] Guerrero M,Li XA.Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy[J].Phys Med Biol,2004,49(20):4825-4835. [14] Song CW,Cho WLC,Yuan J,et al. Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model[J].Int J Radiat Oncol Biol Phys,2013,87(1):18-9.DOI:10.1016/j.ijrobp.2013.03.013. [15] Kocher M,Treuer H,Voges J,et al. Computer simulation of cytotoxic and vascular effects of radiosurgery in solid and necrotic brain metastases[J].Radiother Oncol,2000,54(2):149-156.DOI:10.1016/S0167-8140(99)00168-1. [16] Karasawa K,Sunamura M,Okamoto A,et al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer:long-term results of a placebo-controlled randomised study[J].Radiother Oncol,2008,87(3):326-330.DOI:10.1016/j.radonc.2008.02.007. [17] Guerrero M,Carlone M.Mechanistic formulation of a lineal-quadratic-linear (LQL) model:split-dose experiments and exponentially decaying sources[J].Med Phys,2010,37(8):4173-4181.DOI:10.1118/1.3456927. [18] Brenner DJ.The linear-quadratic model is an appropriate methodology for determining iso-effective doses at large doses per fraction[J].Semin Radiat Oncol,2008,18(4):234-239.DOI:10.1016/j.semradonc.2008.04.004. [19] Mehta N,King CR,Agazaryan N,et al. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy stage Ⅰ non-small cell lung cancer:a pooled analysis of biological equivalent dose and local control[J].Pract Radiat Oncol,2012,2(4):288-295.DOI:10.1016/j.prro.2011.10.004. [20] Gucken-berger M,Klement RJ,Allgäuer M,et al. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer[J].Radiother Oncol,2013,109(1):13-20.DOI:10.1016/j.radonc.2013.09.005. [21] Baker C,Carver A,Nahum A.Local control prediction for NSCLC using a common LQ-based TCP model for both SABR and 3D-CRT fractionation[R].Barcelona:ESTRO,2015:24-28. [22] Kallman RF.The phenomenon of reoxygenation and its implications for fractionated radiotherapy[J].Radiology,1972,105(1):135-142. [23] Brown JM,Diehn M,Loo BW Jr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer[J].Int J Radiat Oncol Biol Phys,2010,78(2):323–327.DOI:10.1016/j.ijrobp.2010.04.070. [24] Loo BW,Shen J,Quinlan-Davidson S,et al. Tumor size is a critical determinant of local control in single fraction stereotactic radiotherapy of pulmonary tumors[J].Int J Radiat Oncol Biol Phys,2008,72(1):S467-468.DOI:10.1016/j.ijrobp.2008.06.1387. [25] Hof H,Muenter M,Oetzel D,et al. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC)[J].Cancer,2007,110(1):148-155.DOI:10.1002/cncr.22763. [26] Goodman KA,Sneed PK,McDermott MW,et al. Relationship between pattern of enhancement and local control of brain metastases after radiosurgery[J].Int J Radiat Oncol Biol Phys,2001,50(1):139-146. [27] Harriss-Phillips WM,Bezak E,Potter A.Stochastic predictions of cell kill during stereotactic ablative radiation therapy:do hypoxia and reoxygenation really matter[J]? Int J Radiat Oncol Biol Phys,2016,95(4):1290-1297. DOI:10.1016/j.ijrobp.2016.03.014. [28] Halberg FE,Cosmatis D,Gunderson LL,et al. RTOG#89-06:a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies[J].Int J Radiat Oncol Biol Phys,1994,28(1):201-206.DOI:10.1016/0360-3016(94)90158-9. [29] Drzymala RE,Wasserman TH,Won M,et al. A phase I-B trial of the radiosensitizer:etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)[J].Radiother Oncol,2008,87(1):89-92.DOI:10.1016/j.radonc.2008.02.006. [30] Park HJ,Griffin RJ,Hui S,et al. Radiation induced vascular damage in tumors:implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)[J].Radiat Res,2012,177(3):311-327.DOI:10.2307/41433198. [31] Song C,Hong BJ,Bok S,et al. The real-time tumor oxygenation changes following a single high dose radiotherapy in orthotopic and subcutaneous lung cancers in mice:clinical implication for stereotactic ablative radiotherapy schedule optimization[J].Int J Radiat Oncol Biol Phys,2016,95(3):1022-1031.DOI:10.1016/j.ijrobp.2016.01.064. [32] Mancuso MR,Davis R,Norberg SM,et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition[J].J Clin Invest,2006,116(10):2610-2621.DOI:DOI:10.1172/JCI24612. [33] Derer A,Deloch L,Rubner Y,et al. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses-Pre-Clinical Evidence and Ongoing Clinical Applications[J].Front Immunol,2015,6:505.DOI:10.3389/fimmu.2015.00505. [34] Yoshimoto Y,Suzuki Y,Mimura K,et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model[J/OL].PLoS One,2014,31,9(3):e92572.DOI:10.1371/journal.pone.0092572. [35] 李佳奇,王皓,杨瑞杰.SBRT联合免疫治疗的机制及研究进展[J].中华放射肿瘤学杂志,2017,26(12):1465-1469.DOI:10.3760/cma.j.issn.1004-4221.2017.12.023. Li JQ,Wang G,Yang RJ.The mechanism and research progress of SBRT combined immunotherapy[J].Chin J Radiat Oncol,2017,26(12):1465-1469.DOI:10.3760/cma.j.issn.1004-4221.2017.12.023. [36] Dewan MZ,Galloway AE,Kawashima N,et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J].Clin Cancer Res,2009,15(17):5379-5388.DOI:10.1158/1078-0432.CCR-09-0265. [37] Demaria S,Kawashima N,Yang AM,et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer[J].Clin Cancer Res,2005,11(2 Pt 1):728-734. [38] Twyman-Saint Victor C,Rech AJ,Maity A,et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377.DOI:10.1038/nature14292. [39] Zegers CM,Rekers NH,Quaden DH,et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res,2015,21(5):1151-1160.DOI:10.1158/1078-0432.CCR-14-2676. [40] Young K,Cottam B,Baird JR,et al. Ideal timing of immunotherapy with radiation in murine tumor models[J].Int J Radiat Oncol,2014,90(1):S58.DOI:doi.org/10.1016/j.ijrobp.2014.05.202. [41] Kalbasi A,June CH,Haas N,et al. Radiation and immunotherapy:a synergistic combination[J].J Clin Invest,2013,123(7):2756-2763.DOI:10.1172/JCI69219. [42] Schaue D,Ratikan JA,Iwamoto KS,et al. Maximizing Tumor Immunity With Fractionated Radiation[J].Int J Radiat Oncol Biol Phys,2012,83(4):1306-10.DOI:10.1016/j.ijrobp.2011.09.049. [43] Nishikawa H,Sakaguchi S.Regulatory T cells in tumor immunity[J].Int J Cancer,2010,127(4):759-67.DOI:10.1002/ijc.25429. [44] Aryankalayil MJ,Makinde AY,Gameiro SR,et al. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells[J].Radiat Res,2014,182(2):139-48.DOI:10.1667/RR13731.1. [45] Lugade AA,Moran JP,Gerber SA,et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor[J].J Immunol,2005,174(12):7516-7523.DOI:10.4049/jimmunol.174.12.7516. [46] Postow MA,Callahan MK,Barker CA,et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J].N Engl J Med,2012,366(10):925-931.DOI:10.1056/NEJMoa1112824. [47] Golden EB,Demaria S,Schiff PB,et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer[J].Cancer Immunol Res,2013,1(6):365-372.DOI:10.1158/2326-6066.CIR-13-0115. [48] Anderson ES,Postow MA,Wolchok JD,et al. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression;efficacy and safety of combined treatment[J].J Immunother Cancer,2017,5(1):76.DOI:10.1186/s40425-017-0282-x. [49] Chen L,Douglass J,Walker AJ,et al. Concurrent immunotherapy and stereotactic radiosurgery for brain metastases is associated with a decreased incidence of new intracranial metastases[J/OL].Int J Radiat Oncol Biol Phys,2015,93(3):E102-E102.DOI:10.1016/j.ijrobp.2015.07.807. [50] US National Library of Science. ClinicalTrials.gov[OL][2018-01-17].https://clinicaltrials.gov/ct2/show/NCT01950195?term=NCT01950195&rank=1(2014). [51] US National Library of Science. ClinicalTrials.gov[OL][2018-01-17].https://clinicaltrials.gov/ct2/results?term=NCT01497808&Search=Search (2014). [52] US National Library of Science. ClinicalTrials.gov[OL][2018-01-17].https://clinicaltrials.gov/ct2/show/NCT02239900?term=NCT02239900&rank=1(2014). [53] US National Library of Science. ClinicalTrials.gov[OL][2018-01-17].https://clinicaltrials.gov/ct2/show/NCT01862900?term=NCT01862900&rank=1(2015). [54] US National Library of Science. ClinicalTrials.gov[OL][2018-01-17].https://clinicaltrials.gov/ct2/show/NCT01401062?term=NCT01401062&rank=1(2015). [55] Sehoenhals JE,Seyedin SN,Tang C,et alPreclinical rationale and clinical considerations for radiotherapy plus immunotherapy:Going beyond local control[J].Cancer J,2016,22(2):130-137.DOI:10.1097/PPO.0000000000000181. [56] Kong F,Liu Y,Zhang H,et al. New risk factors for overall survival after SBRT in early stage NSCLC:a role of RT plan optimization[J].J Thorac Oncol,2017,12(11):S1853.
2018, Vol. 27 
